EASL 2022 上的新型 HBV 药物

StephenW

EASL 2022 上的新型 HBV 药物

大多数 HBV 研究人员似乎已经确定治愈是无法实现的，并且正在寻求功能性治愈，但正如 yiu 从下面的一些新研究中看到的那样，似乎有些研究人员仍然将治愈作为他们的目标......

到目前为止，EASL 收到了 50 多份报告，还有更多报告即将发布
国际肝脏大会™
EASL--欧洲协会
肝脏研究
2022 年 6 月 22-26 日


    EASL：ABI-4334，一种新型乙型肝炎病毒核心蛋白抑制剂，通过破坏进入的衣壳促进空衣壳的形成并防止 cccDNA 的形成 - (06/30/22)
     
    EASL：Assembly Biosciences 在 EASL 的 2022 年国际肝病大会™ 上突出 HBV 核心抑制剂项目的数据 - (06/30/22)
     
    EASL：在停止 AB-729 治疗后维持长期 HBsAg 抑制，并在 HBeAg+ 受试者中观察到相当的治疗反应 - (06/30/22)
     
    EASL：第三代衣壳抑制剂 AB-836 在健康受试者 (HS) 和慢性乙型肝炎 (CHB) 受试者中的安全性、耐受性、药代动力学 (PK) 和抗病毒活性 - (06/30/22)
     
    EASL：RO7049389 加 NUC 加/不加 Peg-IFN 在病毒学抑制和初治慢性乙型肝炎患者中的病毒核酸抑制活性：48 周治疗和治疗后随访 - (06/30/22)
     
    EASL：在用 AB-729 治疗 48 周后，在乙型肝炎表面抗原水平低的慢性乙型肝炎患者中停止核苷（酸）类似物治疗后观察到病毒标志物的持续抑制 - (06/30/22)
     
    EASL：RO7049389 加 NUC 联合/不联合 Peg-IFN 在慢性乙型肝炎患者中的乙型肝炎病毒抗原减少作用 - (06/27/22)
     
    EASL：乙型肝炎血清阴性个体既往丙型和丁型肝炎合并感染的证据 - (06/27/22)
     
    EASL：EASL 2022 HBV、HDV 总结 - (06/27/22)
     
    EASL：siRNA JNJ-3989 和/或衣壳装配调节剂 JNJ-6379 对慢性乙型肝炎病毒标志物的影响：REEF-1 研究结果 - (06/27/22)
     
    EASL：聚乙二醇干扰素 Lambda (IFN-λ) 联合 Lonafarnib 减少了在 IFN-λ 单一疗法下观察到的三相 HDV 动力学模式：LIFT-1 研究 - (06/27/22)
     
    EASL：Madrigal Pharmaceuticals 在 EASL 的国际肝脏大会™上展示了最新的 3 期 NASH 数据和多个口头摘要 - (06/27/22)
     
    EASL：2015-2030 年乙型和丙型肝炎的疾病负担：消除的漫长而曲折的道路 - (06/27/22)
     
    EASL：肝癌 (LC) 和慢性肝病 (CLD) 的全球负担由非酒精性脂肪性肝炎 (NASH) 和酒精性肝病 (ALD) 驱动 - (06/27/22)
     
    EASL：布列韦肽在慢性 Delta 型肝炎中的真实生活研究：ANRS I MIE HD EP01 HDV 前瞻性队列的初步结果 - (06/26/22)
     
    EASL：Antios Therapeutics 的 ATI-2173 在 2a 期研究中证明了对乙型肝炎病毒的抑制； ATI-1428 和 ATI-1645 在非临床研究中表现出有效的抗病毒活性 - (06/26/22)
     
    EASL：改善口服给药后乙型肝炎病毒核心抑制剂 ABI-H3733 的药代动力学特征：新制剂活性的结果 - (06/26/22)
     
    EASL：在恩替卡韦中添加第一代乙型肝炎核心抑制剂 vebicorvir 进行更深的病毒学抑制与 HBeAg 阳性慢性乙型肝炎初治患者的炎症和纤维化 4 指数降低相关 - (06/26/22)
     
    EASL：ATI-2173（一种新型活性位点聚合酶抑制剂核苷酸 (ASPIN) 与富马酸替诺福韦二吡呋酯联合治疗慢性乙型肝炎患者的 2a 期临床试验）持续 12 周的抗病毒疗效 - (06/26/22)
     
    EASL：贝匹罗韦森对慢性乙型肝炎病毒感染患者的疗效和安全性：随机 2b 期 B-Clear 研究的中期结果 - (06/26/22)
     
    EASL：治疗性疫苗 JNJ-0535 在健康成人中诱导强烈的 HBV 特异性 T 细胞反应，在慢性 HBV 感染患者中产生适度反应 VOX/VEL/SOF 在 DAA 失败后有效救援 - 有限制 - (06/26/22 )
     
    EASL：在 HBeAg 阴性病毒学抑制慢性乙型肝炎患者中使用 siRNA JNJ-3989 和衣壳组装调节剂 JNJ-6379 进行有限 48 周治疗的有效性和安全性：REEF-2 研究结果 - (06/25/22)
     
    EASL：三角型肝炎病毒与肝脏发病率和死亡率之间的关联：系统文献回顾和荟萃分析 - (06/25/22)
     
    EASL：评估美国成人中的丙型肝炎病毒疾病流行率和患者特征：对所有付款人索赔数据库的分析 - (06/25/22)

StephenW

New HBV Drugs at EASL 2022

Most HBV researchers appear to have settled n that cure is nt achievable and are seeking functional cure but as yiu can see from some of the new research below there appears to be some researchers who still have as their goal a cure…..

over 50 reports so far from EASL, more coming
The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022


    EASL: ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents cccDNA formation by disruption of incoming capsids - (06/30/22)
     
    EASL: Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022 - (06/30/22)
     
    EASL: Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects - (06/30/22)
     
    EASL: Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) - (06/30/22)
     
    EASL: Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and treatment-naïve chronic hepatitis B patients: 48-week treatment and post treatment follow up - (06/30/22)
     
    EASL: Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729 - (06/30/22)
     
    EASL: Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients - (06/27/22)
     
    EASL: Evidence of Past Hepatitis C and D Co-Infection in Hepatitis B Seronegative Individuals - (06/27/22)
     
    EASL: EASL 2022 HBV, HDV Wrap-Up - (06/27/22)
     
    EASL: Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study - (06/27/22)
     
    EASL: Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (06/27/22)
     
    EASL: Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International Liver Congress™ - (06/27/22)
     
    EASL: The disease burden of hepatitis B and C from 2015- 2030: The long and winding road towards elimination - (06/27/22)
     
    EASL: The Global Burden of Liver Cancer (LC) and Chronic Liver Diseases (CLD) is Driven by Nonalcoholic Steatohepatitis (NASH) and Alcohol Liver Disease (ALD) - (06/27/22)
     
    EASL: Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort - (06/26/22)
     
    EASL: Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study - (06/26/22)
     
    EASL: Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities - (06/26/22)
     
    EASL: Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-naïve patients with HBeAg positive chronic hepatitis B - (06/26/22)
     
    EASL: Sustained 12 Week Off Treatment Antiviral Efficacy of ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), Combined With Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients, a Phase 2a Clinical Trial - (06/26/22)
     
    EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)
     
    EASL: Therapeutic Vaccine JNJ-0535 Induces a Strong HBV-specific T-cell Response in Healthy Adults and a Modest Response in Chronic HBV-infected Patients VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - (06/26/22)
     
    EASL: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study - (06/25/22)
     
    EASL: Association between Hepatitis Delta Virus with Liver Morbidity and Mortality: A Systematic Literature Review and Meta-Analysis - (06/25/22)
     
    EASL: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)

lancas

都是在临床阶段，加油